Clinical Trial Update: Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, PK and PD of SLN360 in subjects with elevated lipoprotein(a) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Elevated Lipoprotein
• Hyperlipidemia

Drugs mentioned

• SLN360

Snippet

Sponsor: Silence Therapeutics plc | Conditions: Hyperlipidemias, Dyslipidemias | Phase 1 | Status: COMPLETED